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Thyroid-stimulating hormone (TSH) controls thyroid growth and hormone secretion through binding to its G protein-coupled receptor
(TSHR) and production of cyclic AMP (cAMP). Serum TSH is a sensitive indicator of thyroid function, and overt abnormalities in thyroid
function lead to common endocrine disorders affecting ~10% of individuals over a life span. By genotyping 362,129 SNPs in 4,300 Sar-
dinians, we identiﬁed a strong association (p ¼ 1.3 3 1011) between alleles of rs4704397 and circulating TSH levels; each additional
copy of the minor A allele was associated with an increase of 0.13 mIU/ml in TSH. The single-nucleotide polymorphism (SNP) is located
in intron 1 of PDE8B, encoding a high-afﬁnity cAMP-speciﬁc phosphodiesterase. The association was replicated in 4,158 individuals,
including additional Sardinians and two genetically distant cohorts from Tuscany and the Old Order Amish (overall p value ¼ 1.9 3
1020). In addition to association of TSH levels with SNPs in PDE8B, our genome scan provided evidence for association with
PDE10A and several biologically interesting candidates in a focused analysis of 24 genes. In particular, we found evidence for association
of TSH levels with SNPs in the THRB (rs1505287, p ¼ 7.33 105), GNAQ (rs10512065, p ¼ 2.03 104), TG (rs2252696, p ¼ 2.23 103),
POU1F1 (rs1976324, p ¼ 3.9 3 103), PDE4D (rs27178, p ¼ 8.3 3 103), and TSHR (rs4903957, p ¼ 8.6 3 103) loci. Overall, the results
suggest a primary effect of PDE8B variants on cAMP levels in the thyroid. This would affect production of T4 and T3 and feedback to alter
TSH release by the pituitary. PDE8B may thus provide a candidate target for the treatment of thyroid dysfunction.Introduction
The thyroid controls several metabolic pathways through
the synthesis and release of thyroxine (T4) and its active
derivative triiodothyroxine (T3), which binds to nuclear
receptors to regulate gene expression and impact growth,
development, and metabolism.1 Consistent with its criti-
cal role in muscle, bone, central nervous system, and heart
physiology, abnormal thyroid function can lead to hyper-
thyroidism, hypothyroidism, and related childhood neu-
ropsychological abnormalities including severe cretinism.2
The key regulator of thyroid function is thyroid-stimu-
lating hormone (TSH). Secreted by the pituitary, TSH inter-
acts with the TSH receptor (TSHR) on thyroid cells to upre-
gulate cyclic AMP (cAMP) and induce Ca2þ release and
activation of phosphoinositol.3 These effectors then lead
to the expression of downstream gene targets, culminating
with pinocytosis of thyroglobulin and the release of T4 and
T3, enhanced iodide uptake, and, on a longer time scale,
growth and differentiation of thyroid follicular cells.
TSH levels are themselves controlled in several ways.
TSH production is promoted by thyrotropin-releasing hor-1270 The American Journal of Human Genetics 82, 1270–1280, Junemone (TRH) and inhibited by somatostatin, both produced
by the hypothalamus.4,5 In addition, negative-feedback
control on hypothalamic release of TRH and pituitary re-
lease of TSH is exerted by the blood levels of thyroid
hormone. When the levels of T3 and T4 are low, the pro-
duction of TRH and TSH increases, and conversely, when
T3 and T4 levels are high, TRH and TSH production
decreases.6
Serum TSH concentrations are a sensitive indicator of
thyroid function. High and low TSH levels reﬂect hypo-
and hyperfunction of the thyroid gland, respectively. How-
ever, even within the normal range, TSH is a sensitive
measure of thyroid function, and normal (euthyroid) indi-
viduals show narrow individual variation, suggesting that
the thyroid-hormone axis is tightly regulated. TSH levels
are genetically regulated and ~40% heritable in several
populations; however, speciﬁc gene variants that inﬂuence
TSH levels are not known.7–9
To identify speciﬁc possible genetic factors affecting TSH
levels and thyroid function, we studied a Sardinian cohort7
in whom the founder-population structure can simplify
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Table 1. Top SNPs Associated with TSH Levels from the GWA in SardiNIA
AffymetrixCode Chr Position dbSNP Allele (þ/) Freq (þ) Effecta SEb H2 c p Value
SNP_A-2026717 5 76554198 rs4704397 A/G 0.43 0.21 0.03 2.32% 1.3 3 1011
SNP_A-2046779 5 76566105 rs6885099 G/A 0.44 0.21 0.03 2.28% 1.8 3 1011
SNP_A-1875128 5 76571567 rs2046045 G/T 0.44 0.21 0.03 2.28% 3.0 3 1011
SNP_A-4219180 9 133168819 rs657152 A/C 0.25 0.18 0.04 1.35% 2.4 3 107
SNP_A-1799335 8 21883108 rs2291317 C/T 0.56 0.14 0.03 1.06% 5.5 3 106
SNP_A-1860723 11 60939964 rs17704641 T/C 0.18 0.17 0.04 0.98% 5.6 3 106
SNP_A-1952455 1 225872467 rs499689 A/G 0.57 0.14 0.03 1.04% 6.0 3 106
SNP_A-4262573 2 222132815 rs2288629 A/C 0.77 0.16 0.04 0.96% 9.2 3 106
SNP_A-1810205 8 21913213 rs17616085 G/A 0.56 0.14 0.03 1.00% 1.0 3 105
SNP_A-2063584 8 21916371 rs3816786 T/A 0.56 0.14 0.03 0.99% 1.2 3 105
SNP_A-1928725 2 85876014 rs4832006 T/C 0.18 0.17 0.04 0.97% 1.4 3 105
SNP_A-2125590 5 76524001 rs6453293 A/G 0.60 0.14 0.03 1.03% 1.9 3 105
SNP_A-1942513 8 21892330 rs1809498 C/G 0.55 0.13 0.03 0.94% 2.0 3 105
SNP_A-1954621 3 184155898 rs7641401 T/C 0.71 0.14 0.03 0.90% 2.3 3 105
SNP_A-4232593 8 21883779 rs4871903 A/G 0.54 0.13 0.03 0.97% 2.3 3 105
SNP_A-2212237 2 17907614 rs300154 G/A 0.47 0.13 0.03 0.87% 2.6 3 105
SNP_A-2148594 5 76497909 rs4361497 G/C 0.69 0.14 0.03 0.88% 3.2 3 105
SNP_A-4265227 1 211014978 rs6656559 A/T 0.31 0.14 0.03 0.88% 3.3 3 105
SNP_A-2071751 6 83147795 rs9344274 T/A 0.25 0.14 0.03 0.86% 3.4 3 105
SNP_A-1849293 6 166027614 rs2983521 A/T 0.76 0.15 0.03 0.85% 3.6 3 105
SNP_A-2293888 5 76553738 rs13158164 C/G 0.11 0.20 0.05 0.83% 3.7 3 105
SNP_A-2039694 8 123942518 rs11779768 A/G 0.70 0.14 0.03 0.86% 3.8 3 105
SNP_A-2276572 4 182013064 rs2545308 G/A 0.59 0.13 0.03 0.87% 3.8 3 105
SNP_A-2192297 8 21889911 rs2306641 C/T 0.57 0.13 0.03 0.87% 3.9 3 105
SNP_A-4274055 2 3406189 rs4849999 C/T 0.91 0.22 0.05 0.83% 3.9 3 105
The table summarizes the top 25 association signals observed in the GWA scan in the Sardinian cohort. Chromosome assignments and physical position refer
to the NCBI build 35 map. Alleles are ordered such that the first allele (þ) is associated with increased TSH levels. SNPs in bold fall in the PDE8B gene
region.
a The effect size is measured in standard-deviation units and is estimated as the b coefficient of the regression model when the normalized trait is used
(e.g., an effect size of 1.0 implies that each additional copy of the allele being evaluated increases trait values by 1.0 standard deviation).
b SE represents the standard error of the effect.
c H2 represents the amount of phenotypic variability explained by the marker and, thus, under an additive model, the amount of the heritability of the trait
explained by the marker.recently facilitated the ﬁnding of genes associated with
susceptibility to asthma,10 obesity-related traits,11 uric
acid,12 lipid levels,13 height,14 and severity of b-thalasse-
mia.15 Here we report analyses that point to common var-
iants in PDE8B [MIM 603390],16 a gene that encodes
a high-afﬁnity cAMP-speciﬁc phosphodiesterase (PDE), as
genetic modulators of TSH levels. The association was rep-The Amlicated in another group of Sardinians and in samples of
Italians from Tuscany and of Old Order Amish from Penn-
sylvania.17,18 Furthermore, our sample provides evidence
for association with single-nucleotide polymorphisms
(SNPs) in the PDE10A gene [MIM 610652],19 as well as thy-
roid-hormone receptor, b (THRB) [MIM 190160]20 (p ¼ 7.3 3
105) and G protein, q polypeptide (GNAQ) (p ¼ 2.0 3 104)Figure 1. Results of Genome-wide Association Scan for TSH Levels
For each marker, the log10 of the p value resulting from an association test that evaluates its additive effect on the phenotype is plot-
ted. The position of PDE8B is annotated.erican Journal of Human Genetics 82, 1270–1280, June 2008 1271
Figure 2. Association with TSH Levels and Linkage-Disequilibrium Patterns in the Region Surrounding PDE8B
(A) The top panel summarizes association between the SNPs and TSH levels in each individual (log10 of the p value). The SNP showing
strongest association (rs4704397) is highlighted and indicated with a red square. Other SNPs are colored according to their degree of
disequilibrium with rs4704397, ranging from high (red) to intermediate (green) to low (blue). r2 values of rs4704397 with rs6885099
and rs2046045 (red dots) are r2 ¼ 0.98 and r2 ¼ 0.97, respectively. The transcript for all genes in the region is indicated in the next
panel, with an arrow indicating transcript direction.
(B) The two panels summarize the patterns of disequilibrium in SardiNIA and in the CEPH from Utah (CEU; Utah residents with ancestry
from northern and western Europe) HapMap populations. r2 values are colored as in (A) with GOLD,30 which schematically draws the LD
plot according to the physical position of markers, resulting in a line divided according to marker-marker distance. The gray bar marks the
region of association and facilitates comparisons between the panels.1272 The American Journal of Human Genetics 82, 1270–1280, June 2008
[MIM 600998],21 among genes in a focused analysis of 24
candidates for involvement in the dynamic regulation of
thyroid function. Overall, our results suggest that PDE8B,
by affecting cAMP concentrations in the thyroid, may alter
thyroid-hormone levels in the serum and affect TSH re-
lease from the pituitary. PDE8B variants thus modulate
thyroid physiology and may affect the course of thyroid
disease.
Material and Methods
Sample Description
We recruited and phenotyped 6,148 individuals, males and fe-
males, ages 14–102 yr, from a cluster of four towns in the Lanusei
Valley of Sardinia.7 During physical examination, a blood sample
was collected from each individual and divided into two aliquots.
One aliquot was used for DNA extraction and the other to charac-
terize several blood phenotypes, including evaluation of serum
TSH levels. TSH wasmeasured with the Siemens TSH assay (Immu-
lite 2000) according to the manufacturer’s instruction. The
method is a solid-phase, chemiluminescent, competitive analog
immunoassay and has analytical sensitivity of 0.004 mIU/ml and
upper limit of 75 mIU/ml of TSH. This method is a third-generation
TSH assay and has a sensitivity and detection range comparable
to the methods used to evaluate TSH levels in the other cohorts
studied (see below).
Thyroid ultrasound examination was also performed on all the
individuals enrolled in the study, with a portable real-time instru-
ment using a 7.5-MHz linear transducer. Subjects were examined
in the supine position, with neck hyperextended, by transverse
and longitudinal scans to evaluate overall thyroid size and echo-
texture. Thyroid volume was calculated for each lobe according
to the ellipsoid formula (length 3 breadth3 width 3 0.523) (nor-
mal range 10.75 4.6 ml to 11.55 3 ml). Goiter was scored when
the total thyroid volume was above the mean thyroid volume. Re-
duction of thyroid volume associated with diffuse alteration of
echotexture indicative of chronic thyropathies was also detected.
Presence, structure, size, and vascularization of nodules were de-
termined by ultrasound and color-Doppler sonography. Records
of self-reported thyroid disease status (i.e., autoimmune thyroid-
itis, thyroid cancer, partial or total thyrectomy) and hormone-
replacement therapy were available for all subjects.
Each participant signed an informed consent form. All study
methods have been approved by the local ethics committee.
GWAS Genotyping
During the study, we genotyped 4,305 individuals selected from
the whole sample to represent the largest available families, re-
gardless of their phenotypic values. Speciﬁcally, 1,412 were geno-
typedwith the 500K AffymetrixMapping Array Set and 3,329 with
the 10K Mapping Array Set, with 436 individuals genotyped with
both arrays. This genotyping strategy allowed us to examine the
majority of our cohort in a cost-effective manner because geno-
types for the SNPs that passed quality-control checks could be
propagated through the pedigree via imputation.11,22 TSH mea-
surements were available for 4,300 individuals among the 4,305The Amgenotyped. A total of 362,129 SNPs passed initial quality-control
checks11 and were tested for association with TSH levels with an
additive model. Further details of the strategy for imputation
and data analysis are given in the Statistical Analysis section be-
low. An additional 1,236 individuals were genotyped with the
10K Mapping Array Set but were not included in the genome-
wide association scan (GWAS) because no close relatives were
typed with the 500K Mapping Array Set. These individuals were,
however, included in the ﬁne-mapping analysis.
Replication and Fine Mapping
We designed a ParAllele Custom Chip (from Affymetrix) to repli-
cate and reﬁne the regions associated with TSH levels as well as
other traits studied in the SardiNIA Project.7,15 Speciﬁcally, for
the locus associated with TSH levels, we included 70 markers
that were chosen as SNP tags of markers falling in the coding re-
gions of the PDE8B gene and that also passed reliability criteria
in the design phase. SNP rs6885099 showed the strongest associa-
tion with TSH levels in an initial analysis performed on a subset of
phenotyped individuals and was thus included in the custom chip
(instead of rs4704397, which ranked second in the initial analy-
sis). Genotyping was performed in Sardinian individuals selected
for replication or for ﬁne-mapping efforts. In particular, for replica-
tion, we genotyped and analyzed 1,858 individuals from the Sardi-
NIA cohort (stage 2), who were unrelated (kinship coefﬁcient ¼ 0)
to the individuals in stage 1.
For ﬁne mapping, we genotyped a subset of 634 individuals
from stages 1 and 2 including 100 couples (mothers and fathers)
already typed with the 500K Mapping Array Set and 434 individ-
uals representing children from the larger sibships.
InCHIANTI
The InCHIANTI study is an ongoing epidemiological study in two
Italian towns in the Chianti area (Tuscany). A detailed description
of the study design and data-collection methods has been pub-
lished.17,23 Plasma TSH levels were measured with commercial
kits (Vitros TSH Reagent, Ortho-Clinical Diagnostics, Johnson &
Johnson Medical S.p.A Section) by chemiluminescent assay. The
assay has an analytical sensitivity of 0.003 mIU/ml. The intra-assay
coefﬁcients of variation (CVs) were 3.9% to 5.3% over the range
0.06–80.11 mIU/ml. SNP rs4704397 was genotyped in this cohort
by TaqMan Single SNP genotyping assays (Applied Biosystems).
Old Order Amish
The Old Order Amish (OOA) study participants reported here were
from ongoing studies of cardiovascular disease and longevity;
none were ascertained on the basis of thyroid disease.18,24 A total
of 1,136 individuals from these two studies had serum TSH mea-
sured by Quest Diagnostics (Nichols Institute) with a standardized
third-generation assay and were previously genotyped for
rs4704397 with the 500K Affymetrix Mapping Array Set.
Statistical Analysis
To evaluate the additive effect of each marker, we ﬁtted a simple
regression model and used a variance-component approach to
account for correlation between different observed phenotypes
within each family. Gender, age, and age squared were included(C) The bottom panel summarizes the results of the fine mapping in the PDE8B gene. The association results are for all SNPs in the
SardiNIA sample genotyped with either the 500K or 10K Mapping Array Set or the ParAllele custom chip. The top three markers, all in
intron 1, are highlighted. The transcripts for all the PDE8B isoforms are indicated at the bottom.erican Journal of Human Genetics 82, 1270–1280, June 2008 1273
as covariates in all analyses, and the trait was normalized with
quantile normalization to avoid inﬂation of type I error rates.
For individuals genotyped with a sparse map, we used a modiﬁed
version of the Lander-Green algorithm25,26 to estimate IBD shar-
ing at the location of the SNPs being tested and identify stretches
of haplotype shared with close relatives who were genotyped at
higher density and probabilistically infer missing genotypes.22
In brief, in the statistical approach to estimate each genotype,
we ﬁrst calculated the likelihood of the observed genotype data.
Then, we assigned each missing genotype to a speciﬁc value and
updated the likelihood pedigree. The ratio of the two likelihoods
gave a posterior probability for the proposed genotype conditional
on all available data. Furthermore, instead of assigning the most
likely genotype, we estimated an expected genotype score, repre-
senting the expected number of copies of a reference allele (a frac-
tional number between 0 and 2), which allowed us to partially
account for uncertainty in genotype assignment. The genotype
scores were then used in a variance-component-based association
test as described.22 Because of computational constraints, we di-
vided large pedigrees into subunits with ‘‘bit-complexity’’26 of 19
or less (typically, 20–25 individuals) before analysis. False-discov-
ery rates (FDRs) were calculated with R’s p.adjust() procedure via
the method of Benjamini and Hochberg.27
In SardiNIA stage 2 replication and in InCHIANTI samples, asso-
ciation with TSH was tested as in the SardiNIA GWA sample, ex-
cept that no imputation was required. Association analyses to
test for additive effects in theOldOrder Amish sample were carried
out under a variance-component framework implemented in
SOLAR;28 these analyses modeled the effect of genotype on TSH
levels while adjusting for the effects of age and sex and accounting
for a background polygenic contribution to variation in TSH levels
occurring because of the relationships existing among the exam-
ined individuals.29 The choice of SOLAR was based on the pres-
ence of larger pedigrees in the OOA families and the lack of a re-
quirement for genotype imputation in these samples.
For ﬁne mapping in the SardiNIA sample, we merged all avail-
able genotypes from all the platforms (500K Mapping Array Set,
10K Mapping Array Set, ParAllele custom chip) for a total of
6,062 nonoverlapping individuals. Because fewer markers were
analyzed than in the GWAS, larger pedigrees were divided into
units of bit-complexity of 21 or less before analysis. Missing geno-
types for individuals typed with only one platform were inferred
with the same approach used in the GWA analysis. We then eval-
uated the additive effect of each marker by using allele dosages as
above.
Results
Genome-wide Association Scan for TSH
Levels in Sardinians
Genome-wide association analyses were carried out in
4,300 volunteers characterized for circulating TSH levels
(see Material and Methods).7,11 Analyses revealed three
SNPs with genome-wide signiﬁcant association at a single
chromosome 5 locus (p < 1010, see Table 1 and Figure 1).
These SNPs and three other SNPs among our top 25 sig-
nals lie in intron 1 or upstream of the PDE8B gene (Table 1
and Figure 2).16 Their locations and linkage-disequilibrium
(LD) relationships in the SardiNIA and CEU HapMap pop-
ulations are illustrated in Figure 2.30,31 A quantile-quantile1274 The American Journal of Human Genetics 82, 1270–1280, Jun(QQ) plot (Figure 3) shows that most of the deviation from
the null hypothesis is accounted for by markers falling in
the PDE8B gene. After those markers were removed, the
corresponding QQ plot (blue line) suggests that there are
nevertheless likely to be some additional true signals (see
below). The three SNPs that showed the strongest ge-
nome-wide signiﬁcant association (rs4704397, p ¼ 1.3 3
1011; rs6885099, p ¼ 1.8 3 1011; rs2046045, p ¼ 3.0 3
1011) are all in strong linkage disequilibrium (Figure 2,
average pairwise r2> 0.98). Among these, the SNP showing
strongest association, rs4704397, explains 2.3% of the var-
iance of TSH levels. Each copy of the minor A allele is asso-
ciatedwith an average increase of 0.13mIU/ml inTSH levels.
Replication of the Association of rs4704397/PDE8B
in Other Populations
To conﬁrm the association of rs4704397 with TSH levels,
we analyzed two additional cohorts, one comprising
1,164 Tuscan subjects from the genetically distinct In-
CHIANTI study population17,23 and the second 1,136 indi-
viduals from the founder population of the Old Order
Amish.18,24 We also analyzed a replication cohort of 1,858
individuals enrolled in the SardiNIA study but unrelated
to the ﬁrst group (designated here as stage 2 analysis). The
features of these cohorts are given in Table 2, and the results
of association are summarized in Table 3. Analysis revealed
that SNP rs4704397 or its surrogate rs6885099 was associ-
ated with the TSH trait in all the cohorts tested, with the
same direction of effect as observed in our original sample
(Table 3). Notably, the effect size in the replication samples
Figure 3. Quantile-Quantile Plot of SNPs Associated with TSH
Level in the SardiNIA Study
Red dots represent all the 362,129 SNPs analyzed in the GWAS. Blue
dots represent all analyzed SNPs not located within the PDE8B
gene. The gray area corresponds to the 90% confidence region
from a null distribution of p values generated from 100 simula-
tions.e 2008
Table 2. Characteristics of Samples Used in Genome-wide and Follow-Up Analyses
Population Study n (% female) Mean Age (SD) Mean TSH (SD) % Under Treatment
% Recorded
Disease Status
SardiNIA 4300 (56.2%) 43.6 (17.6) 2.04 (3.2) 2.5% 81%
Follow-up samples
SardiNIA stage 2 1858 (59.9%) 44.6 (17.4) 2.23 (4.4) 2.2% 81%
InCHIANTI 1164 (55.9%) 68.8 (15.4) 1.92 (4.7) 6.1% 100%
Old Order Amish 1136 (47.0%) 49.9(16.7) 2.19 (2.5) 6.8% NA
The table shows the mean and standard deviation (SD) for age and TSH values for each study group, as well as the percentage of individuals under thyroid-
hormone therapy and of individuals with clear reports of disease status (i.e., thyroid cancer, surgery, and autoimmune thyroiditis). NA, not assessed.was about half that observed in the initial GWAS (0.25 ver-
sus 0.12). This may be due to less accurate estimates of ef-
fect size as a result of reduction in sample size and conse-
quent decrease of statistical power, or it may reﬂect the
‘‘winner’s curse’’ phenomenon, where effect-size estimates
for markers that reach statistical signiﬁcance may be in-
ﬂated. The combined p value from stage 2 analyses in the
three cohorts was highly signiﬁcant (p ¼ 2.0 3 1010),
leading to a cumulative-association p value of 1.93 1020.
Table 3 also summarizes the distribution of the TSH
levels for each genotype class for the SNP rs4704397 and
shows that in all the samples, individuals carrying at least
one copy of the minor A allele have higher circulating
levels of TSH than those homozygous for the major G al-
lele, showing a trend for an additive model. In the Amish
sample, the mean TSH value for individuals with the A/G
genotype appears slightly higher than that observed for
the A/A subjects. This could result from the different fre-
quency of the rare A allele and the lower frequency of
the A/A genotype in the Amish compared with the other
cohorts; this lower frequency would yield less accurate
mean-value estimates for this genotype class compared to
values in the other cohorts.
We also repeated association analyses in all cohorts after
stratifying subjects into two groups, one group including
individuals with TSH levels in the normal range (0.4–4.0
mIU/ml), with no reported history of thyroid disease, and
not taking thyroid medications (group 1, Table 4), andThe Amthe other group including the remaining subjects (group
2). The results conﬁrmed the association of rs4704397 in
both the unaffected and the thyroid-affected individuals
(Table 4). Because of the reduction in sample size, the p
value was lower in the two subsets, but the effect size of
the associated A allele was larger in group 2 individuals
(in all but the OOA cohort), suggesting a potential involve-
ment of PDE8B activity in the course of thyroid disease.
Further analysis in a larger subgroup of thyroid-affected
Sardinian subjects, including all the individuals from
group 2 as well as individuals with nodules and goiters
(formerly in group 1), showed stronger association when
compared to the remaining subjects, again conﬁrming
a larger effect size of the A allele in thyroid-affected indi-
viduals (see Table S1 available online). Despite the consis-
tently larger effect in thyroid-affected individuals in sev-
eral studies, this difference does not reach statistical
signiﬁcance (Cochran’s Q statistic32 p ¼ 0.49, I2 ¼ 0%);
consequently, larger studies will be necessary to test this
hypothesis further. Association analysis of rs4704397 in
males and females did not suggest gender-speciﬁc effects
(Table S2). Signals for other loci that did not reach ge-
nome-wide signiﬁcance (Table 1) did not replicate strongly
in other cohorts and have in general not been followed up
further. For two SNPs, rs657152 on chromosome 9 (in the
ABO blood group gene [MIM 110300], with borderline Bon-
ferroni p value) and SNP rs2983521 on chromosome 6 (in
PDE10A,19 a gene that belongs to the same enzyme familyTable 3. Summary of Association Results for SNP rs4704397 in All Cohorts
Population Study n A/A A/G G/G Freq(A) Effecta (SE) p Value
SardiNIAb 4300 1.60 (1.50) 1.38 (1.21) 1.20 (1.14) 0.44 0.25 (0.04) 1.3 3 1011
Stage 2
SardiNIA stage 2c 1858 1.84 (1.43) 1.67 (1.30) 1.49 (1.32) 0.44 0.13 (0.03) 1.1 3 104
InCHIANTI 1164 1.50 (2.12) 1.32 (1.14) 1.26 (1.18) 0.41 0.12 (0.04) 0.0021
Old Order Amish 1136 1.75 (1.54) 1.80 (1.42) 1.55 (1.33) 0.33 0.12 (0.05) 7.0 3 105
Meta-analysis
Stage2 4158 2.0 3 1010
Overall 8458 1.9 3 1020
The table summarizes association results for rs4704397 in all cohorts. For each study, genotype medians (IRQ range) of unadjusted TSH values are reported
in mIU/ml; effect sizes (SE) and p values are given relative to the normalized trait.
a The effect size is measured in standard-deviation units and is estimated as the b coefficient of the regression model when the normalized trait is used
(e.g., an effect size of 1.0 implies that each additional copy of the allele being evaluated increases trait values by 1.0 standard deviation).
b SardiNIA genotype medians are relative only to individuals directly genotyped with the 500K Mapping Array Set.
c Results are for rs6885099, in strong LD (r2 ¼ 0.98) with rs4704397, which was not genotyped (see Material and Methods).erican Journal of Human Genetics 82, 1270–1280, June 2008 1275
Table 4. Results of Association Analysis of rs4704397 in Healthy and Thyroid-Affected Individuals
Group 1 Group 2
Population Study n Effecta (SE) p Value n Effecta (SE) p Value
SardiNIA 3785 0.18 (0.03) 1.5 3 108 515 0.26 (0.08) 1.3 3 103
Stage 2
SardiNIA stage 2b 1645 0.12 (0.03) 7.9 3 104 213 0.24 (0.10) 0.013
InCHIANTIc 994 0.08 (0.05) 0.067 191 0.24 (0.10) 0.016
Old Order Amishd 962 0.15 (0.05) 5.7 3 104 174 0.11 (0.11) 0.104
Meta-analysis Meta-analysis
Stage 2 3601 5.4 3 107 578 1.5 3 104
Overall 7386 4.3 3 1014 1093 7.2 3 107
We compared association results in two subgroups. Group 1 identifies healthy subjects and consists of individuals with TSH levels in the normal range of
0.4–4 mIU/dl and with no history of thyroid disease (thyroid medications, thyroid cancer, surgery, or autoimmune thyroiditis). Group 2 consists of the
remaining subjects.
a The effect size refers to the minor allele frequency (MAF) allele; it is measured in standard-deviation units and is estimated as the b coefficient of the
regression model when the normalized trait is used (e.g., an effect size of 1.0 implies that each additional copy of the allele increases trait values by 1.0
standard deviation).
b Results are for rs6885099, in strong LD (r2 ¼ 0.98) with rs4704397, which was not genotyped (see Materials and Methods).
c Thryoid autoimmunity and thyroid cancer information were not reported in the InCHIANTI database. Old Older Amish database did not contain any in-
formation regarding thyroid disease, so only out-of-range TSH values and history of taking thyroid-hormone therapy were considered to define group 2.
d Old Older Amish database did not contain information regarding thyroid disease, so only out-of-range TSH values and history of taking thyroid-hormone
therapy were considered to define group 2.as PDE8B), some further testing was performed. SNP
rs657152 did not replicate in the Amish or InCHIANTI co-
horts, whereas rs2983521 was replicated in InCHIANTI,
with a one-sided p value of 0.048, but was not supported
in the Amish samples (data not shown). Thus, its involve-
ment in the variability of TSH remains suggestive, requir-
ing study in additional cohorts.
Fine Mapping in the PDE8B Locus
To identify possible coding and/or functional variants in-
volved in the regulation of PDE8B activity in the context
of TSH variation, we genotyped 70 additional SNPs falling
in the PDE8B gene or in the neighboring 5 kb upstream
and downstream regions in 2,492 Sardinians. We analyzed
all the available markers (39 from the GWAS and 70 from
the custom chip) in the individuals genotyped with at least
one platform and for whom TSH values were available (n¼
6,062). As shown in Figure 2C and Table S3, the strongest
association signals all pointed to intron 1, common to all
ﬁve PDE8B isoforms, in which ten signiﬁcant SNPs were lo-
cated. The top three SNPs conﬁrmed the previous top three
markers detected in the GWAS, though with a shifted rank
order (rs6885099, p¼ 1.693 1014; rs4704397, p¼ 1.013
1012; rs2046045, p ¼ 3.76 3 1012). Several of the SNPs
show linkage disequilibrium (r2 > 0.5) with SNPs in neigh-
boring regions (Figures 2A and 2B), suggesting that the
functional variant(s) may lie outside of intron 1. However,
it seems likely that they will reside in a noncoding se-
quence, because sequence analysis of all the PDE8B exons
in 20 subjects homozygous for the rare and 20 for the com-
mon alleles of the top two associated SNPs, rs4704397 and
rs6885099, did not reveal any coding variants (data not
shown). In addition to intron 1, we also found evidence
of association for two new SNPs within intron 10 of1276 The American Journal of Human Genetics 82, 1270–1280, JunePDE8B1. The functional relevance of these variants re-
mains to be elucidated. Further studies, including large-
scale resequencing and molecular analyses, will be neces-
sary to verify the effects of the associated variants on the
regulation of the TSH levels.
Association Analysis of Candidate Genes
with TSH Levels
Our GWA analysis implicated PDE8B as the only gene with
a signiﬁcant effect on variation of TSH. Because PDE8B var-
iants contribute only 2.3% of TSH variation, which repre-
sents a small part of the total genetic component of the
trait (~40%), we expected other genes to contribute to
TSH levels, albeit with smaller effects. To begin to look
for such genes, we carried out in the SardiNIA cohort a sub-
analysis focusing on candidate genes, where a less strin-
gent signiﬁcance threshold would increase power. We se-
lected 24 candidate genes on the basis of their reported
function in cAMP metabolism, TSH signaling, and the reg-
ulation of thyroid function. No linkage and association
studies showing a correlation with TSH levels had previ-
ously been performed for any of these candidates. When
markers falling in the candidates and already genotyped
in the GWAS were tested for their association with TSH
levels, as expected none reached genome-wide signiﬁcant
association (Table 5). However, substantive evidence of as-
sociation was detected for some genes involved in the bio-
logical activity and negative feedback of thyroid hormone
(THRB),20 in signaling of TSH (TSHR [MIM 603372] and
GNAQ),21,33 in thyroid-hormone production (TG [MIM
188450]),33 and in phosphodiesterases involved in the ca-
tabolism of cAMP (PDE4D [MIM 600129])34,35 (see Discus-
sion for more details). Among the various PDE genes,
PDE4D and PDE7B [MIM 604645]36 were included in the2008
Table 5. Tag SNPs that Show Strongest Association with TSH in Previously Identified Candidate Genes in the TSH Signaling
Pathways and Thyroid Function
Gene
# Affymetrix
SNPs
# HapMap
SNPs
Coverage
(0.5)
Coverage
(0.8)
Best
p Value SNP
Allele
(þ/) Freq (þ) Effecta H2
THRB 58 382 0.67 0.45 7.3 x105 rs1505287 G/A 0.67 0.16 1.27%
GNAQ 20 204 0.91 0.75 2.0 x104 rs10512065 G/A 0.85 0.13 0.49%
TG 76 489 0.95 0.86 2.2 x103 rs2252696 A/C 0.47 0.08 0.37%
POU1F1 1 9 1.00 0.78 3.9 x103 rs1976324 G/A 0.66 0.12 0.74%
PDE4D 119 714 0.82 0.61 8.3 x103 rs27178 G/A 0.46 0.07 0.24%
TSHR 21 221 0.87 0.61 8.6 x103 rs4903957 G/A 0.69 0.09 0.34%
GNAO1 22 157 0.87 0.70 0.01 rs2550298 T/C 0.52 0.05 0.11%
DIO1 5 16 0.88 0.69 0.03 rs2294512 G/A 0.83 0.12 0.43%
PDE7B 39 196 0.85 0.61 0.03 rs9376165 G/A 0.82 0.14 0.60%
GNAI1 8 70 0.83 0.40 0.04 rs2523189 C/T 0.76 0.10 0.32%
GNAS 6 36 0.61 0.39 0.05 rs6026565 A/T 0.14 0.06 0.09%
TTF1 0 19 0.32 0.16 0.08 rs7030233 G/A 0.18 0.08 0.23%
TPO 17 176 0.81 0.53 0.09 rs2071403 G/A 0.54 0.09 0.45%
DIO2 0 12 0.83 0.67 0.09 rs9919906 C/T 0.59 0.08 0.32%
TSH-A 2 11 1.00 0.91 0.13 rs6155 C/T 0.06 0.09 0.11%
PAX8 10 41 0.88 0.66 0.16 rs6716573 T/C 0.22 0.08 0.24%
PROP1 0 3 0.67 0.00 0.23 rs4413548 T/C 0.51 0.02 0.03%
TRHR 8 37 0.86 0.70 0.25 rs3134115 T/C 0.44 0.02 0.02%
CREBBP 8 23 0.61 0.57 0.29 rs8046065 C/T 0.81 0.01 0.00%
CREB1 2 19 0.74 0.74 0.32 rs2709393 A/G 0.06 0.02 0.00%
CTLA4 0 2 1.00 0.50 0.36 rs11571292 G/A 0.80 0.03 0.03%
TSH-B 0 4 1.00 1.00 0.66 rs2274118 G/C 0.28 0.02 0.02%
THRA 1 4 0.25 0.25 0.84 rs939348 C/T 0.85 0.00 0.00%
PRKAR1B 0 2 0.00 0.00 NA NA NA NA NA NA
The first column indicates the name of a previously identified candidate gene. The second column indicates the number of SNPs in our Affymetrix arrays
that are within 5 5 kb of the gene. The next column indicates the number of HapMap SNPs within 5 5 kb of the gene and the proportion of these
that are covered at r2 ¼ 0.50 or r2 ¼ 0.80 by SNPs in the Affymetrix arrays. The remaining columns indicate the SNP that showed strongest association
in our analysis, the p value, the tested allele and its frequency, and the estimated additive effect in standard-deviation units. Association was tested
either with intragenic SNPs or with the best available tag for intragenic SNPs (r2 > 0.5). Shown in bold are candidate genes with SNPs reaching
p values % 0.05.
a The effect size refers to the MAF allele; it is measured in standard-deviation units and is estimated as the b coefficient of the regression model when the
normalized trait is used (e.g., an effect size of 1.0 implies that each additional copy of the allele increases trait values by 1.0 standard deviation).focused analysis on the basis of their cAMP speciﬁcity and
reported expression in thyroid tissues. We have calculated
the corresponding FDRs27 by taking into account all the
503 SNPs tested in the candidate-gene analysis. Notably,
by this criterion, the q value for SNPs falling in the THRB
and GNAQ genes reached the signiﬁcant threshold of
0.05 (q ¼ 0.036 and q ¼ 0.050, respectively), suggesting
a possible involvement in the variability of TSH levels.
Discussion
The PDE8B gene, encoding a high-afﬁnity cAMP phospho-
diesterase,37 is inferred to modulate circulating TSH levels
in three independent populations, with a combined p
value of 1.9 3 1020. Of the ﬁve characterized PDE8B iso-
forms, the major isoform PDE8B1 and minor isoforms
PDE8B2 and PDE8B3 are abundantly expressed in the thy-
roid.16,38 Because PDE8B is undetectable in the pituitary,39
we infer it to act primarily in the thyroid to catalyze the hy-
drolysis and inactivation of cAMP after TSH signaling.
PDE8B could then inﬂuence TSH levels by feedback from
an effect on the generation of T4 and T3 in the thyroid,The Amin line with reports that both thyroglobulin endocytosis
and thyroid-hormone secretion are stimulated by TSH via
a cAMP-dependent pathway.3
Although no signals other than PDE8B reached genome-
wide signiﬁcance (Table 5), several candidate genes showed
suggestive evidence of association. These included two
other cAMP-speciﬁc phosphodiesterases, PDE4D,34,35 and,
at amuch lower level of signiﬁcance, PDE7B.36 It is relevant
that the cAMP-speciﬁc PDE4 family has also been sug-
gested to be involved in modulating the cAMP signal after
TSH stimulation of thyrocytes.34 Furthermore, some evi-
dence for association was also detected in our GWAS in
PDE10A, a phosphodiesterase with dual speciﬁcity for cy-
clic nucleotides and stimulated by cAMP.19 Analyses using
differential inhibition or transfection of the range of phos-
phodiesterases and their variants in thyrocytes should help
to determine their contribution to cAMP levels.
As for other genes previously implicated in TSH homeo-
stasis, the thyroid-hormone receptor, b (THRB)20 and several
G protein genes—in particular, GNAQ,21 previously re-
ported to be required for TSH-induced thyroid-hormone
synthesis and release—implicated in the signal transduc-
tion of hormone receptors, also showed suggestiveerican Journal of Human Genetics 82, 1270–1280, June 2008 1277
association signals (Table 5). Finally, some evidence of as-
sociation was also noticed in two thyroid-speciﬁc genes,
thyroglobulin (TG) and thyroid-stimulating hormone receptor
(TSHR),33 and in POU class 1 homeobox 1 (POU1F1 [MIM
173110]),40 a gene expressed in the pituitary and impor-
tant for the regulation of a number of pituitary hormones.
We infer that much of the TSH-level variance that subtly
affects normal and possibly pathological states seems to be
exerted at the level of cAMP degradation. It is possible that
genomic PDE8Bmutations could be responsible for certain
thyroid diseases—for example, for increased serum TSH
occasionally observed in individuals with no evidence of
thyroid autoimmunity or loss-of-function mutations in
the thyroid-hormone- or TSH-receptor genes.41 Because
PDE8B has the highest afﬁnity for cAMP of any known
phosphodiesterase,37 the enzyme would be active even at
low concentrations of cAMP, and a change in its level or
activity could have an especially marked effect on TSH
signaling. Consistent with this notion, a mutation in
PDE8B that leads to elevated cAMP levels has now been
identiﬁed in a case of adrenal hyperplasia in Cushing syn-
drome (AIMAH [MIM 219080]).42 Increased cAMP-degrad-
ing PDE8B activity has also been detected in autonomous
thyroid adenomas, where it may represent a compensatory
mechanism opposing the constitutive activation of the
cAMP pathway.34 Other reports have noted PDE8B upregu-
lation in Alzheimer’s disease (AD [MIM 104300]) brain43
and pituitary adenomas,39 as well as involvement in
a model of modiﬁed insulin secretion.44
PDE family members have increasingly been implicated
in the pathogenesis of a number of other diseases, includ-
ing cardiovascular disorders, renal failure,45 adrenocortical
hyperplasia,42,46 and a wide variety of inﬂammatory pa-
thologies.47 Selective isoform-speciﬁc PDE inhibitors are
already employed to treat several diseases, and thus
PDE8B may provide a pharmaceutical target for certain
thyroid pathologies.
Supplemental Data
Five tables are available at http://www.ajhg.org/.
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